

List of Supporting Information

Table S1 The PDB ID, Resolution, and ligand of key antihypertensive target proteins.....	2
Table S2 Molecular docking results of compounds 1–8 and 4IP with AKT1.....	2
Table S3 Molecular docking results of compounds 1–8 and HEM with HMOX1	3
Table S4 Molecular docking results of compounds 1–8 and OGE with IL1B	3
Table S5 Molecular docking results of compounds 1–8 and QC5 with TP53.....	4
Table S6 Molecular docking results of compounds 1–8 and FCM with PPARG	4
Table S7 Molecular docking results of compounds 1–8 and M60 with CASP3	5
Table S8 Molecular docking results of compounds 1–8 and S58 with PTGS2.....	5
Table S9 Molecular docking results of compounds 1–8 and NFH with MMP9.....	6
Table S10 Molecular docking results of compounds 1–8 and TAM with IL6	6
Table S11 Molecular docking results of compounds 1–8 and J8S with TNF.....	7
Table S12 Molecular docking results of compounds 1–8 and PGE with VEGFA	7
Figure S1 Physicochemical property of compound 1.....	8
Figure S2 Physicochemical property of compound 2.....	8
Figure S3 Physicochemical property of compound 3.....	9
Figure S4 Physicochemical property of compound 4.....	9
Figure S5 Physicochemical property of compound 5.....	10
Figure S6 Physicochemical property of compound 6.....	10
Figure S7 Physicochemical property of compound 7.....	11
Figure S8 Physicochemical property of compound 8.....	11
Explanation of ADMET parameters	12

Table S1 The PDB ID, Resolution, and ligand of key antihypertensive target proteins

Protein name	PDB ID	Resolution	ligand
AKT1	1H10	1.40 Å	4IP
HMOX1	1N3U	2.58 Å	HEM
IL1B	6Y8I	1.46 Å	OGE
TP53	3ZME	1.35 Å	QC5
PPARG	4F9M	1.90 Å	FCM
CASP3	2CNO	1.95 Å	M60
PTGS2	1CX2	2.50 Å	S58
MMP9	1GKC	2.50 Å	NFH
IL6	4CNI	2.20 Å	TAM
TNF	6M95	2.10 Å	J8S
VEGFA	4KZN	1.71 Å	PGE

Table S2 Molecular docking results of compounds **1–8** and 4IP with AKT1

Compound	Total score	D score	PMF score	G score	Chem score
1	3.44	-74.053	-71.159	-112.147	-13.443
2	3.64	-70.650	-63.846	-70.530	-13.779
3	3.98	-65.762	-58.895	-91.343	-16.205
4	4.66	-85.889	-86.186	-106.026	-12.966
5	3.51	-13.189	-56.705	-60.669	-9.099
6	3.28	-78.261	-39.557	-194.694	-16.571
7	4.32	-61.079	-32.208	-179.342	-10.646
8	4.62	-87.836	-36.382	-260.459	-17.918
4IP	5.98	-48.012	-143.012	-194.068	-13.498

Table S3 Molecular docking results of compounds **1–8** and HEM with HMOX1

Compound	Total score	D score	PMF score	G score	Chem score
1	4.03	-68.122	-39.851	-105.929	-22.720
2	4.06	-60.460	-85.007	-66.168	-24.324
3	3.75	-84.772	-64.966	-68.313	-23.863
4	4.03	-95.782	-5.389	-82.090	-16.303
5	4.48	-83.601	-85.627	-109.933	-28.416
6	5.40	-137.510	-36.002	-278.728	-32.859
7	5.86	-128.771	-33.895	-289.629	-29.490
8	7.49	-145.967	-34.850	-270.829	-31.043
HEM	8.27	-86.281	-98.644	-277.994	-32.101

Table S4 Molecular docking results of compounds **1–8** and OGE with IL1B

Compound	Total score	D score	PMF score	G score	Chem score
1	2.44	-37.858	-4.850	-38.409	-17.731
2	2.53	-73.397	-10.047	-42.211	-16.718
3	2.50	-82.995	4.465	-94.224	-17.021
4	2.33	-61.975	12.163	-14.360	-12.317
5	2.81	-49.081	-0.611	-63.809	-16.957
6	4.59	-88.232	-2.073	-187.598	-19.785
7	3.76	-81.894	22.197	-189.869	-18.316
8	2.85	-81.706	25.221	-211.133	-18.405
OGE	2.00	-47.576	-0.576	-99.549	-14.355

Table S5 Molecular docking results of compounds **1–8** and QC5 with TP53

Compound	Total score	D score	PMF score	G score	Chem score
1	5.65	-95.392	-10.846	-144.441	-24.458
2	4.96	-110.224	-10.457	-126.099	-23.774
3	4.73	-104.131	-22.832	-111.218	-23.918
4	4.53	-88.282	15.579	-88.097	-27.063
5	7.12	-18.759	-11.411	-161.403	-29.133
6	4.20	-99.367	-3.999	-232.905	-27.059
7	3.77	-107.117	-2.787	-249.463	-29.379
8	2.84	-137.566	30.816	-327.175	-34.674
QC5	6.67	-124.784	-14.885	-226.399	-25.582

Table S6 Molecular docking results of compounds **1–8** and FCM with PPARG

Compound	Total score	D score	PMF score	G score	Chem score
1	6.00	-87.502	-38.172	-168.580	-17.283
2	5.41	-95.390	-33.089	-146.513	-13.040
3	4.96	-81.465	-27.739	-117.609	-15.130
4	5.78	-97.250	-26.639	-91.229	-12.635
5	5.36	-102.315	-31.963	-181.459	-10.470
6	6.08	-142.011	-21.708	-296.967	-29.151
7	6.40	-136.066	-0.108	-297.624	-29.631
8	2.97	-130.456	-11.265	-297.539	-27.475
FCM	3.01	-65.667	-11.102	-120.571	-5.491

Table S7 Molecular docking results of compounds **1–8** and M60 with CASP3

Compound	Total score	D score	PMF score	G score	Chem score
1	5.18	-104.625	-54.078	-162.852	-27.096
2	4.05	-94.283	-51.990	-76.712	-22.200
3	4.93	-84.487	-51.125	-73.216	-23.400
4	4.17	-79.798	-57.424	-49.724	-22.652
5	3.44	-83.626	-41.796	-96.562	-22.305
6	4.62	-108.880	-25.860	-240.709	-22.901
7	5.51	-109.110	-34.816	-227.409	-26.529
8	6.44	-114.898	-38.129	-244.968	-26.743
M60	8.59	-146.063	-60.820	-220.227	-23.630

Table S8 Molecular docking results of compounds **1–8** and S58 with PTGS2

Compound	Total score	D score	PMF score	G score	Chem score
1	7.82	-125.209	-58.629	-160.359	-39.568
2	7.39	-129.593	-29.479	-184.334	-27.885
3	5.81	-115.115	-54.928	-124.993	-32.835
4	7.16	-132.958	-38.810	-169.767	-30.726
5	8.22	-124.114	-24.931	-211.148	-30.091
6	-15.62	-219.671	10.172	-472.648	-53.117
7	-16.71	-220.209	22.418	-504.628	-57.175
8	-17.77	-223.336	27.920	-509.312	-54.334
S58	10.75	-153.753	-45.251	-272.545	-39.578

Table S9 Molecular docking results of compounds **1–8** and NFH with MMP9

Compound	Total score	D score	PMF score	G score	Chem score
1	5.71	-127.202	-46.410	-185.087	-29.568
2	6.00	-133.343	-58.431	-69.460	-31.362
3	4.92	-88.556	-22.494	-103.205	-26.737
4	5.23	-91.010	-36.383	-97.464	-30.403
5	6.64	-146.615	-79.150	-202.252	-28.303
6	7.29	-156.627	-34.718	-312.573	-34.838
7	6.72	-160.340	-36.958	-328.195	-36.106
8	8.35	-155.041	19.425	-338.679	-35.076
NFH	6.88	-124.640	-39.648	-242.251	-28.888

Table S10 Molecular docking results of compounds **1–8** and TAM with IL6

Compound	Total score	D score	PMF score	G score	Chem score
1	3.96	-83.381	-71.012	-135.144	-23.229
2	3.31	-185.122	-75.774	-52.178	-20.020
3	3.42	-79.299	-70.680	-29.576	-24.519
4	3.77	-85.207	-47.734	-109.807	-28.898
5	3.59	-78.878	-60.724	-96.696	-27.763
6	4.85	-98.020	-51.367	-204.518	-26.413
7	4.94	-108.777	-40.211	-241.678	-27.594
8	4.79	-101.125	-39.533	-203.667	-25.808
TAM	4.78	-58.236	-13.254	-71.158	-13.693

Table S11 Molecular docking results of compounds **1–8** and J8S with TNF

Compound	Total score	D score	PMF score	G score	Chem score
1	6.62	-113.372	-47.326	-186.038	-27.315
2	7.47	-124.730	-37.670	-140.382	-28.165
3	5.76	-125.129	-36.957	-134.548	-24.091
4	5.12	-114.498	-24.947	-107.169	-23.315
5	5.82	-123.609	-34.001	-175.624	-27.016
6	0.14	-187.952	14.163	-423.263	-46.017
7	2.73	-190.575	26.669	-434.088	-44.872
8	0.53	-187.790	18.590	-457.151	-47.409
J8S	12.16	-165.413	6.652	-310.906	-41.635

Table S12 Molecular docking results of compounds **1–8** and PGE with VEGFA

Compound	Total score	D score	PMF score	G score	Chem score
1	2.22	-58.808	24.333	-56.055	-13.675
2	2.07	-57.233	21.622	-5.160	-15.178
3	1.56	-51.860	-17.601	7.712	-17.387
4	1.96	-71.346	-22.110	-41.604	-17.094
5	2.62	-56.975	17.058	-37.584	-17.856
6	2.40	-68.018	2.006	-170.650	-16.690
7	2.57	-68.226	18.405	-174.744	-16.246
8	2.88	-74.133	2.522	-181.525	-17.857
PGE	3.19	-59.453	8.716	-67.605	-7.587




Figure S1 Physicochemical property of compound 1.




Figure S2 Physicochemical property of compound 2.




Figure S3 Physicochemical property of compound 3.




Figure S4 Physicochemical property of compound 4.




Figure S5 Physicochemical property of compound 5.




Figure S6 Physicochemical property of compound 6.




Figure S7 Physicochemical property of compound 7.




Figure S8 Physicochemical property of compound 8.

Explanation of ADMET parameters

1. Physicochemical property

1.1 Molecular Weight

Contain hydrogen atoms. Optimal:100~600, based on Drug-Like Soft rule.

1.2 Volume

Van der Waals volume.

1.3 Density

Density = MW / Volume

1.4 nHA

Number of hydrogen bond acceptors. Sum of all O and N. Optimal: 0~12, based on Drug-Like Soft rule.

1.5 nHD

Number of hydrogen bond donors. Sum of all OHs and NHs. Optimal:0~7, based on Drug-Like Soft rule.

1.6 nRot

Number of rotatable bonds. In some situation Amide C-N bonds are not considered because of their high rotational energy barrier. Optimal:0~11, based on Drug-Like Soft rule.

1.7 nRing

Number of rings. Smallest set of smallest rings. Optimal:0~6, based on Drug-Like Soft rule.

1.8 MaxRing

Number of atoms in the biggest ring. Number of atoms involved in the biggest system ring. Optimal:0~18, based on Drug-Like Soft rule.

1.9 nHet

Number of heteroatoms. Number of non-carbon atoms (hydrogens included). Optimal:1~15, based on Drug-Like Soft rule.

1.10 fChar

Formal charge. Optimal:-4 ~4, based on Drug-Like Soft rule

1.11 nRig

Number of rigid bonds. Number of non-flexible bonds, in opposite to rotatable bonds.

Optimal:0~30, based on Drug-Like Soft rule.

1.12 Flexibility

Flexibility = nRot / nRig

1.13 Stereo Centers

Number of stereocenters. Optimal: ≤ 2 , based on Lead-Like Soft rule.

1.14 TPSA

Topological polar surface area. Sum of tabulated surface contributions of polar fragments.

Optimal:0~140, based on Veber rule.

1.15 logS

The predicted solubility of a compound is given as the logarithm of the molar concentration (log mol/L). Compounds in the range from -4 to 0.5 log mol/L will be considered proper.

1.16 logP

The predicted logP of a compound is given as the logarithm of the molar concentration (log mol/L). Compounds in the range from 0 to 3 log mol/L will be considered proper.

1.17 logD7.4

The predicted logD7.4 of a compound is given as the logarithm of the molar concentration (log mol/L). Compounds in the range from 1 to 3 log mol/L will be considered proper.

2. Absorption

2.1 Caco-2 Permeability

The predicted Caco-2 permeability of a given compound is given as the log cm/s. A compound is considered to have a proper Caco-2 permeability if it has predicted value $> -5.15 \log \text{ cm/s}$.

2.2 MDCK Permeability

The unit of predicted MDCK permeability is cm/s. A compound is considered to have a high passive MDCK permeability for a $P_{\text{app}} > 20 \times 10^{-6} \text{ cm/s}$, medium permeability for $2-20 \times 10^{-6} \text{ cm/s}$, low permeability for $< 2 \times 10^{-6} \text{ cm/s}$.

2.3 F_{20%}

Molecules with a bioavailability $\geq 20\%$ were classified as $F_{20\%}$ - (Category 0), while molecules with a bioavailability $< 20\%$ were classified as $F_{20\%}$ + (Category 1). The output value is the probability of being $F_{20\%}$ +, within the range of 0 to 1. Empirical decision: 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

3. Distribution

3.1 PPB

A compound is considered to have a proper PPB if it has predicted value $< 90\%$, and drugs with high protein-bound may have a low therapeutic index. Empirical decision: $\leq 90\%$: excellent; otherwise: poor.

3.2 BBB Penetration

The unit of BBB penetration is cm/s. Molecules with $\log_{BB} > -1$ were classified as BBB+ (Category 1), while molecules with $\log_{BB} \leq -1$ were classified as BBB- (Category 0). The output value is the probability of being BBB+, within the range of 0 to 1. Empirical decision: 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

4. Metabolism

4.1 CYP1A2 / 2C19 / 2C9 / 2D6 / 3A4 inhibitor, CYP1A2 / 2C19 / 2C9 / 2D6 / 3A4 substrate

Based on the chemical nature of biotransformation, the process of drug metabolism reactions can be divided into two broad categories: phase I (oxidative reactions) and phase II (conjugative reactions). The human cytochrome P450 family (phase I enzymes) contains 57 isozymes and these isozymes metabolize approximately two-thirds of known drugs in human with 80% of this attribute to five isozymes—1A2, 3A4, 2C9, 2C19 and 2D6. Most of these CYPs responsible for phase I reactions are concentrated in the liver.

Category 0: Non-substrate / Non-inhibitor; Category 1: substrate / inhibitor. The output value is the probability of being substrate / inhibitor, within the range of 0 to 1.

5. Excretion

5.1 CL

The unit of predicted CL penetration is ml/min/kg. >15 ml/min/kg: high clearance; 5-15 ml/min/kg: moderate clearance; <5 ml/min/kg: low clearance. Empirical decision: ≥ 5 : excellent; < 5: poor.

5.2 $T_{1/2}$

Molecules with $T_{1/2} > 3$ were classified as $T_{1/2}^-$ (Category 0), while molecules with $T_{1/2} \leq 3$ were classified as $T_{1/2}^+$ (Category 1). The output value is the probability of being $T_{1/2}^+$, within the range of 0 to 1. Empirical decision: 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

6. Toxicology

6.1 H-HT

The human hepatotoxicity. Category 0: H-HT negative (-); Category 1: H-HT positive (+). The output value is the probability of being toxic, within the range of 0 to 1. Empirical decision: 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

6.2 DILI

The drug-induced liver injury. Category 0: DILI negative (-); Category 1: DILI positive (+). The output value is the probability of being toxic, within the range of 0 to 1. Empirical decision: 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

6.3 AMES Toxicity

The Ames test for mutagenicity. Category 0: AMES negative (-); Category 1: AMES positive (+). The output value is the probability of being toxic, within the range of 0 to 1. Empirical decision: 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

6.4 Rat Oral Acute Toxicity

Determination of acute toxicity in mammals (rat). Category 0: low-toxicity, > 500 mg/kg; Category 1: high-toxicity; < 500 mg/kg. The output value is the probability of being toxic, within the range of 0 to 1. Empirical decision: 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.